End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9,980 KRW | -2.16% | +7.43% | -1.96% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.96% | 144M | - | ||
+12.80% | 130B | A- | ||
-8.69% | 10.99B | A- | ||
-4.33% | 8.35B | C | ||
+41.38% | 5.67B | B+ | ||
-23.95% | 4.72B | C | ||
+7.68% | 3.42B | C- | ||
-10.23% | 2.76B | B- | ||
-14.30% | 1.92B | - | ||
-27.77% | 1.68B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A156100 Stock
- Ratings L&K Biomed Ltd.